Aligos Therapeutics presents positive data at APASL2025

Aligos Therapeutics (ALGS) announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver, APASL, 2025, being held March 26 – 30, 2025 in Beijing, China. Data from less than or equal to84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated HBV DNA suppression in 9/9 HBeAg+ subjects. All HBeAg- subjects achieved sustained HBV DNA suppression by Week 24 and 11/11 subjects achieved sustained HBV DNA less thanLLOQ at Week 48 with 10/11 subjects further achieving HBV DNA below the lower limit of detection. Importantly, no subject demonstrated viral resistance to ALG-000184 monotherapy and suppression was maintained throughout the dosing period. Additionally, the third oral presentation will highlight the best-in-class potential of ALG-055009, a purpose built THR-beta agonist discovered by Aligos scientists. 12-weeks of once daily ALG-055009 treatment in MASH patients met the primary endpoint, with robust reductions in liver fat content at Week 12. Doses of 0.5 mg to 0.9 mg ALG-055009 demonstrated statistically significant reductions in liver fat at Week 12, with placebo-adjusted median relative reductions up to 46.2% as measured by MRI-PDFF